TY  - JOUR
AU  - Marth, Christian
AU  - Tarnawski, Rafal
AU  - Tyulyandina, Alexandra
AU  - Pignata, Sandro
AU  - Gilbert, Lucy
AU  - Kaen, Diego
AU  - Rubio, M. Jesus
AU  - Frentzas, Sophia
AU  - Beiner, Mario
AU  - Magallanes-Maciel, Manuel
AU  - Farrelly, Laura
AU  - Choi, Chel Hun
AU  - Berger, Regina
AU  - Lee, Christine
AU  - Vulsteke, Christof
AU  - Hasegawa, Kosei
AU  - Braicu, Elena Ioanna
AU  - Wu, Xiaohua
AU  - McKenzie, Jodi
AU  - Lee, John J.
AU  - Makker, Vicky
PY  - 2021
DO  - 10.1136/ijgc-2021-003017
SN  - 1048-891X
UR  - https://hdl.handle.net/10668/25441
T2  - International journal of gynecological cancer
AB  - Background Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of...
LA  - en
PB  - Bmj publishing group
TI  - Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
TY  - research article
VL  - 32
ER  -